RecruitingNCT06278532

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Validation of the Lithuanian Version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and the Schizophrenia Cognition Rating Scale


Sponsor

Lithuanian University of Health Sciences

Enrollment

200 participants

Start Date

Dec 11, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • age 18 - 65 years old;
  • Diagnosis of F20, F25 or F21 according to ICD-10;
  • Signed informed consent form.

Exclusion Criteria6

  • Age younger than 18 or older than 65 years old;
  • Did not sign the informed consent form;
  • Legally inactive person
  • Patients with a comorbid or primary diagnosis of mental retardation according to ICD-10 (F70 - F79);
  • Patients with a comorbid or primary diagnosis of mental and behavioural disorders due to psychoactive substance use (F10 - F19)
  • Patients with a comorbid of primary diagnosis of organic, including symptomatic, mental disorders (F00 - F09)

Interventions

DIAGNOSTIC_TESTThe Schizophrenia Cognition Rating Scale

The Lithuanian version of the SCoRS will be used and validated. SCoRS is a 20-item interview-based assessment tool that evaluates cognitive deficits and the degree to which these deficits impair specifically in patients with schizophrenia.

DIAGNOSTIC_TESTBrief Negative Symptoms Scale

The Lithuanian Brief Negative Symptoms scale (BNSS) version will be used and validated. BNSS is used as a modern tool for the evaluation of negative symptoms of schizophrenia. Older tools used for negative symptoms evaluation often include symptoms from other dimensions of symptoms of schizophrenia, and BNSS evaluates negative symptoms specifically. BNSS is a semi-structured interview made of 13 items. There are six subscales: anhedonia (3 items), lack of normal distress (1 item), asociality (2 items), avolition (2 items), blunted affect (3 items) and alogia (2 items).

DIAGNOSTIC_TESTThe Calgary Depression Scale for Schizophrenia

The Lithuanian version of the CDSS will be used and validated. CDSS is a tool used to evaluate depressive symptoms, specifically for patients with schizophrenia. Often, distinguishing between depressive and negative symptoms of schizophrenia is difficult. Therefore, it is recommended to use tools designed specifically for patients with schizophrenia. CDSS is the only depression scale designed to assess depression in people with a schizophrenia syndrome disorder. It is a semi-structured interview consisting of 9 items.


Locations(2)

Lithuanian University of Health Sciences Hospital Kaunas Clinics

Kaunas, Lithuania

Jonas Montvidas

Kaunas, Lithuania

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06278532


Related Trials